Comparative Efficacy of Valsartan and Valsartan-Hydrochlorothiazide combination Therapy in Hypertensive Heart Disease Patients: a Clinical and Ultrasonographic Study
Abstract
Objective: This study aimed to evaluate the clinical efficacy and ultrasound diagnostic outcomes of valsartan combined with hydrochlorothiazide in the treatment of hypertensive patients with heart disease.
Material & Methods: A total of 160 patients diagnosed with hypertension and concomitant heart disease who received treatment at Federal Institute of Health Sciences affiliated hospital were enrolled from June 2025 to Sep 2025 and randomly assigned into two equal groups of 80 each. The control group received valsartan monotherapy, while the study group was administered valsartan in combination with hydrochlorothiazide. The therapeutic efficacy and incidence of adverse reactions
were compared between the two groups.
Results: Results demonstrated that the study group exhibited a significantly higher overall treatment efficacy and a lower rate of adverse reactions compared to the control group (P<0.05). Post-treatment comparisons revealed greater improvements in both systolic and diastolic blood pressure in the study group (P<0.05). Ultrasonic echocardiographic assessments indicated superior recovery in the study group with respect to left ventricular mass index, posterior wall thickness, and ejection fraction (P<0.05).
Conclusion: In conclusion, combination therapy with valsartan and hydrochlorothiazide markedly enhances clinical outcomes and reduces adverse events in hypertensive patients with heart disease, supporting its broader clinical adoption..
Downloads
References
Mushtaq A, Khaliq T, Sher HA, Farid A, Kanwal A, Sarfraz M. Pharmacokinetic study of clarithromycin in human female of Pakistani population.
Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs. 2002 Sep;62(13):1983-2005.
Wagstaff AJ. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs. 2006 Oct;66(14):1881-901.
Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, Grosso A. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Current medical research and opinion. 2008 Aug 1;24(8):2303-11.
Chazova IY, Sirenko Y, Vincelj J, Widimsky Jr J, Barbič-Žagar B. The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension—the VICTORY trial. Polish Heart Journal (Kardiologia Polska). 2017;75(1):55-64.
Waeber B, Aschwanden R, Sadecky L, Ferber P. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. Journal of hypertension. 2001 Nov 1;19(11):2097-104.
Destro M, Crikelair N, Yen J, Glazer R. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vascular health and risk management. 2010 Sep 7:821-7.
Geiger H, Barranco E, Gorostidi M, Taylor A, Zhang X, Xiang Z, Zhang J. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. The Journal of Clinical Hypertension. 2009 Jun;11(6):324-32.
Raij L, Egan BM, Zappe DH, Purkayastha D, Samuel R, Sowers JR. Office and Ambulatory Blood Pressure–Lowering Effects of Combination Valsartan/Hydrochlorothiazide vs Hydrochlorothiazide‐Based Therapy in Obese, Hypertensive Patients. The Journal of Clinical Hypertension. 2011 Oct;13(10):731-8.
Widimsky Jr J, Vincelj J, Sirenko Y, Yevgenyevna IC, Zagar BB. The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with…. Polish Heart Journal (Kardiologia polska). 2018;76(2):328-37.
Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clinical therapeutics. 2007 Jan 1;29(1):61-73.
Kondrack R, Mohiuddin S. Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy. Expert opinion on drug metabolism & toxicology. 2009 Sep 1;5(9):1125-34.
White WB, Murwin D, Chrysant SG, Koval SE, Davidai G, Guthrie R. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood pressure monitoring. 2008 Feb 1;13(1):21-7.
Chrysant SG. Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan®/HCT). Expert Review of Cardiovascular Therapy. 2003 Oct 1;1(3):335-43.
Marfatia R, White WB, Schumacher H. Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate‐to‐Severe Hypertension. International Journal of Hypertension. 2012;2012(1):976828.
Deeks ED. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. American journal of cardiovascular drugs. 2009 Dec;9(6):411-8.
Izzo Jr JL, Weintraub HS, Duprez DA, Purkayastha D, Zappe D, Samuel R, Cushman WC. Treating Systolic Hypertension in the Very Elderly With Valsartan‐Hydrochlorothiazide vs Either Monotherapy: ValVET Primary Results. The Journal of Clinical Hypertension. 2011 Oct;13(10):722-30.
Weir MR, Levy D, Crikelair N, Rocha R, Meng X, Glazer R. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. American journal of hypertension. 2007 Jul 1;20(7):807-15.
Zhou X, Chu Y. Efficacy of the combination of valsartan and hydrochlorothiazide in the treatment of hypertensive heart disease. Tropical Journal of Pharmaceutical Research. 2023 Sep 15;22(8):1741-7.
Tuomilehto J, Tykarski A, Baumgart P, Reimund B, Le Breton S, Ferber P. Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. Blood Pressure. 2008 Jan 1;17(sup1):15-23.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
